journal
Journals Rheumatic Diseases Clinics of ...

Rheumatic Diseases Clinics of North America

https://read.qxmd.com/read/38670733/rheumatic-immune-related-adverse-events-current-clinical-imperatives-underpin-future-novel-insights
#1
EDITORIAL
David F L Liew, Alexa Simon Meara
No abstract text is available yet for this article.
May 2024: Rheumatic Diseases Clinics of North America
https://read.qxmd.com/read/38670732/-not-available
#2
EDITORIAL
Michael H Weisman
No abstract text is available yet for this article.
May 2024: Rheumatic Diseases Clinics of North America
https://read.qxmd.com/read/38670731/impact-of-non-steroidal-anti-inflammatory-drugs-glucocorticoids-and-disease-modifying-anti-rheumatic-drugs-on-cancer-response-to-immune-checkpoint-inhibitor-therapy
#3
REVIEW
Karmela K Chan, Anne R Bass
Immune checkpoint inhibitor (ICI) therapy for advanced malignancies often leads to off-target adverse events. Rheumatic immune-related adverse events can often linger beyond the duration of ICI therapy and sometimes requires the use of immunomodulator therapy. A key question, therefore, is if the commonly used therapies affect cancer outcomes. In this review, the authors summarize the state of the data as it currently stands, taking into consideration the limitations of the various source studies. The most information is known about glucocorticoids, which appear to be harmful especially when used early and at high doses...
May 2024: Rheumatic Diseases Clinics of North America
https://read.qxmd.com/read/38670730/the-need-for-classification-criteria-of-immune-checkpoint-inhibitor-induced-inflammatory-arthritis-a-scoping-review
#4
REVIEW
Nilasha Ghosh, Bridget Jivanelli, Nina Couette, Namrata Singh, Marie Kostine, Alexa Simon Meara, David F L Liew
Immune checkpoint inhibitor-induced inflammatory arthritis (ICI-IA) is an immune-related adverse event that can occur as a result of receiving ICIs for cancer treatment. Thus far, ICI-IA has been described variably in the literature, in part due to varying presentations that evolve over time, as well as a lack of standardized definitions and classification. This scoping review aggregates various descriptions of ICI-IA, highlighting the most prominent attributes of ICI-IA from categories such as symptoms, signs, imaging, and laboratory findings as well as discussing potential mimic conditions...
May 2024: Rheumatic Diseases Clinics of North America
https://read.qxmd.com/read/38670729/imaging-in-rheumatic-immune-related-adverse-events
#5
REVIEW
Jeremy Zhang, Ruoning Ni, Ibiyemi Oke, Cassandra Calabrese, Jennifer Strouse, Sophia Weinmann, Alexandra Ladouceur
Since their introduction, immune checkpoint inhibitors have revolutionized cancer treatment by harnessing the body's own immune system as a defense against tumor growth. The downside of activating the immune system is the development of immune-related adverse events (irAEs), which mimic autoimmune disease of various organ systems. The musculoskeletal system is an uncommon, but substantial one for patients and can lead to long-term pain and disability that affects their quality of life. This review summarizes recent literature on imaging forms utilized for diagnosis and assessing treatment response in rheumatic irAEs...
May 2024: Rheumatic Diseases Clinics of North America
https://read.qxmd.com/read/38670728/de-novo-connective-tissue-disorders-as-immune-related-adverse-events
#6
REVIEW
Lindsay Kristin Cho, Shahin Jamal
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment through blocking immunoregulatory pathways, resulting in augmented antitumor responses. However, ICIs can cause inflammatory autoimmune toxicities, known as immune-related adverse events (irAEs). Common rheumatic irAEs include inflammatory arthritis, polymyalgia rheumatica-like symptoms, and myositis. Fewer cases of de novo connective tissue disease as irAEs have been described and have mainly presented with cutaneous manifestations of systemic lupus erythematosus (SLE) and systemic sclerosis (SSc)...
May 2024: Rheumatic Diseases Clinics of North America
https://read.qxmd.com/read/38670727/immune-checkpoint-inhibitor-induced-sicca-syndrome
#7
REVIEW
Samuel Bitoun, Antoine Rousseau, Marjolaine Gosset, Rakiba Belkhir, Thierry Lazure, Xavier Mariette, Gaetane Nocturne
The development of sicca in patients treated with immune checkpoint inhibitors (ICIs) is undoubtedly an underestimated complication, but one whose functional consequences and impact on quality of life are significant for patients. This update aims to review the frequency of this complication and different clinical pictures. The authors also propose a diagnostic and therapeutic approach to guide clinicians in daily practice.
May 2024: Rheumatic Diseases Clinics of North America
https://read.qxmd.com/read/38670726/immune-checkpoint-inhibitor-induced-myositis
#8
REVIEW
Athira Jayan, Andrew L Mammen, Maria E Suarez-Almazor
Myositis induced by immune checkpoint inhibitors (ICIs) is an infrequent, potentially fatal, immune-related adverse event. It has higher incidence in patients who receive combination ICI therapy compared to monotherapy. Patients can present with clinical manifestation symptoms of myositis alone or in combination with myocarditis and/or myasthenia gravis, which significantly worsens the course and prognosis. Diagnosis can generally be made on the basis of clinical presentation, elevation of muscle enzymes, and electromyographic changes, but some patients may require a muscle biopsy...
May 2024: Rheumatic Diseases Clinics of North America
https://read.qxmd.com/read/38670725/immune-checkpoint-inhibitor-induced-inflammatory-arthritis-current-approaches-to-management
#9
REVIEW
Namrata Singh, Anupama Shahane, Jeffrey A Sparks, Samuel Bitoun, Laura C Cappelli
The introduction of immune checkpoint inhibitors (ICIs) has changed the landscape of the treatment of cancer. Several immune-related adverse events (irAEs) have now been described such as ICI-inflammatory arthritis (IA), sicca syndrome, polymyalgia rheumatica, myositis, and vasculitis as a consequence of immune activation. The onset of the ICI-IA can vary from after the first infusion of ICIs to a delayed presentation a year or more after ICI initiation. Ultimately, baseline patient and tumor characteristics, the types of immunotherapies used, pre-existing autoimmune diseases, and/or other irAEs, as well as patient preferences will all shape the discussions around ICI-IA management...
May 2024: Rheumatic Diseases Clinics of North America
https://read.qxmd.com/read/38670724/immune-checkpoint-inhibitor-induced-polymyalgia-rheumatica
#10
REVIEW
David F L Liew, Sarah L Mackie, Alice Tison, Sebastian E Sattui, Max Yates, Russell R C Buchanan, Claire E Owen
Polymyalgia rheumatica (PMR) immune-related adverse events (ICI-PMRs) represent a novel, distinct entity, despite many clinical, laboratory, and imaging similarities to classical PMR. Important questions remain in differentiating ICI-PMR from classical PMR, as well as other immune-related adverse events and PMR mimics. Despite this, ICI-PMR currently takes treatment cues from classical PMR, albeit with considerations relevant to cancer immunotherapy. Comparisons between ICI-PMR and classical PMR may provide further bidirectional insights, especially given that important questions remain unanswered about both diseases...
May 2024: Rheumatic Diseases Clinics of North America
https://read.qxmd.com/read/38670723/patient-voices-in-rheumatic-immune-related-adverse-events
#11
REVIEW
Kara N Corps, Oliver Terry, Maria A Lopez-Olivo
Patients with cancer considering immune checkpoint inhibitor (ICI) therapy often look for health information and peer support through online communities. The authors used social media content analysis to obtain the perspectives of patients receiving ICI treatment about immune-related adverse events (irAEs), with particular focus on rheumatological symptoms. The most reported rheumatic symptom was joint pain. Other commonly reported symptoms included muscle pain, joint stiffness, arthritis, myositis, bone pain, back pain, and tendon/ligament pain...
May 2024: Rheumatic Diseases Clinics of North America
https://read.qxmd.com/read/38670722/immunotherapy-toxicity-management-in-clinical-practice-building-the-clinical-infrastructure-for-immune-related-adverse-event-evaluation-and-care
#12
REVIEW
Yael Klionsky, Alexa Simon Meara, Pankti Reid
Cancer immunotherapy is revolutionary for survival but has complications due to immunogenicity with unpredictable and potentially long-lasting autoimmune side effects known as immune-related adverse events (irAEs). Currently, treatment beyond corticosteroids can be complicated by the diversity of providers who are needed across a variety of clinical settings to manage irAEs. We outline the role of critical players in the management of irAEs, discuss the current limitations that exist, and propose various methodologies that can be adapted across clinical settings to tackle these needs...
May 2024: Rheumatic Diseases Clinics of North America
https://read.qxmd.com/read/38670721/the-current-and-future-of-biomarkers-of-immune-related-adverse-events
#13
REVIEW
William Bracamonte-Baran, Sang T Kim
With their groundbreaking clinical responses, immune checkpoint inhibitors (ICIs) have ushered in a new chapter in cancer therapeutics. However, they are often associated with life-threatening or organ-threatening autoimmune/autoinflammatory phenomena, collectively termed immune-related adverse events (irAEs). In this review, we will first describe the mechanisms of action of ICIs as well as irAEs. Next, we will review biomarkers for predicting the development of irAEs or stratifying risks.
May 2024: Rheumatic Diseases Clinics of North America
https://read.qxmd.com/read/38670720/the-utility-of-laboratory-investigations-for-the-assessment-and-management-of-rheumatic-immune-related-adverse-events
#14
REVIEW
Alexandra Ladouceur, Aiarpi Ezdoglian, Jeffrey A Sparks, Marie Hudson, Shahin Jamal, Alison Clifford, Janet Roberts, Carrie Ye
Immune checkpoint inhibitors (ICIs) have greatly improved survival of several cancers with historically very poor prognosis. ICIs act by stimulating the patient's own immune system to fight cancer. Simultaneously, this immune activation can lead to immune-related adverse events (irAEs), including rheumatic manifestations (Rh-irAEs). Rh-irAEs mimic primary rheumatic diseases including arthritis, polymyalgia rheumatica, myositis, vasculitis, sarcoidosis, and sicca. This article summarizes the latest evidence regarding the utility of laboratory investigations in Rh-irAEs...
May 2024: Rheumatic Diseases Clinics of North America
https://read.qxmd.com/read/38670719/mimickers-of-immune-checkpoint-inhibitor-induced-inflammatory-arthritis
#15
REVIEW
José A Gómez-Puerta, Karolina Gente, Tamiko R Katsumoto, Jan Leipe, Pankti Reid, Wouter H van Binsbergen, Maria E Suarez-Almazor
The differential diagnosis of inflammatory arthritis as an immune-related adverse event can be challenging as patients with cancer can present with musculoskeletal symptoms that can mimic arthritis because of localized or generalized joint pain. In addition, immune checkpoint inhibitors can exacerbate joint conditions such as crystal-induced arthritis or osteoarthritis, or induce systemic disease that can affect the joints such as sarcoidosis. This distinction is important as the treatment of these conditions can be different from that of immune-related inflammatory arthritis...
May 2024: Rheumatic Diseases Clinics of North America
https://read.qxmd.com/read/38670718/pre-existing-autoimmune-diseases-and-immune-checkpoint-inhibitors-for-cancer-treatment-considerations-about-initiation-flares-immune-related-adverse-events-and-cancer-progression
#16
REVIEW
Jeffrey A Sparks
Immune checkpoint inhibitors (ICIs) are increasingly used to treat a variety of cancer types. Patients with preexisting autoimmune diseases may be vulnerable to underlying disease flare as well as immune-related adverse events from ICIs. There has also been concern that immunosuppression needed to control the autoimmune disease may blunt ICI efficacy. Much of the literature is focused on diverse preexisting autoimmune diseases, which may limit conclusions to specific diseases. There is a growing literature of specific diseases, such as preexisting rheumatoid arthritis, investigating outcomes after ICI...
May 2024: Rheumatic Diseases Clinics of North America
https://read.qxmd.com/read/37973292/preface
#17
EDITORIAL
Michael H Weisman
No abstract text is available yet for this article.
February 2024: Rheumatic Diseases Clinics of North America
https://read.qxmd.com/read/37973291/eric-bywaters-and-barbara-ansell-founders-of-modern-pediatric-rheumatology
#18
JOURNAL ARTICLE
Patricia Woo, Ross E Petty
Eric Bywaters and Barbara Ansell were, without doubt, two of the giants in the field of Rheumatology. With their keen clinical observations and their visionary development of a dedicated multidisciplinary program focusing on diagnosis, treatment, and research, they are remembered as the founders of the modern specialty of Pediatric Rheumatology.
February 2024: Rheumatic Diseases Clinics of North America
https://read.qxmd.com/read/37973290/walter-bauer-marian-wilkins-ropes-and-the-massachusetts-general-hospital
#19
REVIEW
Anthony M Reginato, Michelle A Petri, Jonathan Kay
Walter Bauer was instrumental in the development of rheumatology as a medical subspecialty, promoting careful clinical observation and description and bringing basic scientists and clinicians together to study the "anatomy, chemical composition, and metabolism of connective tissue" in the laboratory. Marian Wilkins Ropes was a pioneering woman in medicine: the first female medical resident at the Massachusetts General Hospital, the first woman appointed as an assistant professor of clinical medicine at Harvard Medical School, the first woman elected to membership in the American Society of Clinical Investigation, and the first woman elected president of the American Rheumatism Association...
February 2024: Rheumatic Diseases Clinics of North America
https://read.qxmd.com/read/37973289/lessons-from-carl-m-pearson-1919-1981
#20
REVIEW
James S Louie
Carl M. Pearson was an energetic and exceptional physician-scholar-leader who founded, established, and broadened the Divisions of Rheumatology at University of California in Los Angeles (UCLA) beginning in 1956. His studies to induce myositis by injecting muscle saturated with the heat-killed tubercle bacillus, an emulsifier, and mineral oil (Freund's adjuvant) enabled his report that polyarthritis occurred with Freund's adjuvant alone in certain strains of rat and mice. This model of adjuvant arthritis allowed the next generation of studies to assess therapies for autoimmune diseases...
February 2024: Rheumatic Diseases Clinics of North America
journal
journal
29572
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.